Advanced hybrid theranostic nanoplatforms for an active drug delivery in the cancer treatment

Principal Investigator: Silvia Panseri
Involved Personnel: Monica Montesi, Giada Bassi, Aurora Grimaudo

Starting date: 01/01/2021
Duration: 36 months
Total funding: 744.898 €
Call: H2020-WIDESPREAD-2020-5
Coordinator: Vaclav Ranc (Univerzita Palackeho V Olomouci (CZ))
Consortium: 3 partners (Univerzita Palackeho V Olomouci; National University of Irelan Maynooth; ISTEC-CNR)

Official website: nano4tarmed.com

Cancer is one of the leading causes of death worldwide. Great efforts are still necessary to individuate new therapeutic strategies aimed to reduce cancer recurrence and to define new potential adjuvant targets for inhibiting invasion and metastasis, two significant contributors to death among patients. The combination therapy based on the simultaneous administration of two or more pharmacologically active agents with different modes of action using nanocarriers for the delivery could represent an effective strategy for the treatment. This project aims at an establishment of a consortium consisted of Regional centre of advanced technologies and materials (part of Palacký University), The Institute of Science and Technology for Ceramics (part of CNR) and Maynooth University which will through a set of workshops, seminars and extensive exchange of early-stage researchers develop an efficient scientific cluster. The research of the cluster will aim the development of functional 3D dual-modality nanostructures for targeted drug delivery and cell imaging.